Note: results can be filtered by year and/or keyword. To filter on year, select the appropriate year from the drop down menu. To filter on keyword, enter relevant term into open box, select appropriate keyword, and click "filter".
Statements, Speeches, Letters
MSF is deeply disappointed with both the report of the meeting of Member States on the CEWG report and the draft Resolution. Despite a clear restatement of the failures of the current R&D system to deliver affordable, accessible and appropriate medical tools to meet the needs of people in developing countries, Member States are being asked to pass - unopened - an extremely weak Resolution which threatens to change nothing.
Last updated 25 January 2013
Distinguished Delegate, We are writing to express our deep concern at the lack of ambition and apparent inaction of the WHO and Member States in taking forward the work of the Consultative Expert Working Group on Research and Development: Financing and Coordination (CEWG). This inaction is costing lives.
Last updated 25 January 2013
Final hearings begin in Bayer's appeal against Indian move to allow production of more affordable cancer drug
Further compulsory licences on high-price patented medicines expected 18 January 2013 - This week, final hearings began in Chennai, India, in the appeal that German pharmaceutical company Bayer has filed against India’s first-ever compulsory licence (CL). In a related development, India is currently identifying other patented drugs on which CLs are needed. Bayer case
Last updated 18 January 2013
MSF addresses study by Massachusetts General Hospital on implications of switching from branded to generic antiretrovirals for HIV
Study on generic antiretrovirals ignores fact that patents prevent use of more affordable patient-friendly combination drugs
“It’s time to put an end to the fact that one in five babies born every year still misses out on basic vaccination that can protect them from childhood killers. In the often unstable and remote places where we work, we need vaccines that don’t require refrigeration, can be delivered without needles and can be given in fewer doses so we can get to the hardest-to-reach children.
Last updated 7 December 2012
“The lack of private sector research and development for neglected diseases (just 10% in 2011 for sleeping sickness, leishmaniasis and Chagas disease), reflects the core problem that today’s R&D model relies on market incentives and high prices for a return on investment. The costs of investing in R&D must be separated from the price of resulting products.
Last updated 3 December 2012
From 26-28th November, Government representatives are gathered at the WHO in Geneva to decide how to take forward the recommendations of the report of the Consultative Expert Working Group on R&D Financing and Coordination, including the call for an R&D Convention. MSF along with 60 other civil society organisations have sent this open letter to Governments to ask that they focus on concrete measures to address the failures in the current R&D system.
Last updated 27 November 2012
Government representatives are gathering for the next 3 days at the WHO in Geneva to decide how to take forward the recommendations of the report of the Consultative Expert Working Group on R&D Financing and Coordination, including the call for an R&D Convention. MSF was given the opportunity to speak during the opening plenary of this otherwise closed meeting.
Last updated 26 November 2012
“It’s encouraging to see the number of new child infections declining as a result of more pregnant women having access to HIV treatment in 2011, compared to the year before. Still just over half of pregnant women with HIV in developing countries get treatment which is unacceptable, considering it can prevent their babies from acquiring the virus, while also keeping the mothers themselves healthy.
Last updated 20 November 2012
“Let’s be honest: Vaccine data, pricing, and adaptability in Africa” Opening remarks by Daniel Berman, General Director, Médecins Sans Frontières / Doctors Without Borders (MSF) South Africa (MSF SA) Thank you for the introduction, and the opportunity to participate in this distinguished panel.
Last updated 15 November 2012